☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Monaleesa-3
Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale
September 22, 2020
Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women
August 1, 2019
Load more...
Back to Home
